A lung drug that slows aging: the quiet revolution in repurposing medicines

The drug that outlives its first job

In 2025, Insilico Medicine developed rentosertib to fight a deadly lung disease. But the researchers suspected their drug had a secret second career. When they ran patient blood through six different proteomic aging clocks, all six agreed: rentosertib wasn't just healing lungs — it appeared to be slowing biological aging itself. The Nature Biotechnology study turned a single treatment into something rarer: a glimpse of medicine doing double duty.

That same repurposing instinct is rippling across laboratories worldwide, as researchers keep discovering that drugs already in our arsenal can fight far more than they were built for.

A cancer drug takes a detour to the heart

At Yale, Martin Schwartz's team found that a protein complex called PRC2, linked to disturbed blood flow, helps drive the inflammation behind atherosclerosis — the plaque buildup behind heart attacks. Associate research scientist Divyesh Joshi led the work, published in PNAS, showing that an existing cancer drug could tame that very inflammation. Meanwhile, at Marshall University's Joan C. Edwards School of Medicine, Bruno Goncalves and colleagues found a separate lever: blocking a signaling pathway in fat cells reduced plaque formation in mice, published in Arteriosclerosis, Thrombosis, and Vascular Biology L. Two labs, two angles, one shared question — how do we calm the silent buildup in our arteries?

Timing the kidney rescue

At National Taiwan University Hospital, researchers studying adults with type 2 diabetes recovering from severe kidney injury found that starting an SGLT-2 inhibitor within 30 days of discharge beat waiting 31 to 90 days. Adverse kidney events dropped from 6.2% to 3.9%. The JAMA Network Open finding answers a real clinical dilemma: clinicians often hesitate to prescribe these powerful drugs while kidneys are still settling back down.

The first evidence for a neglected condition

Lipedema affects almost exclusively women — a painful fat-distribution disorder marked by leg pain, bruising, and swelling. For decades, the only answer was compression, drainage, and exercise, which help but rarely relieve pain fully. The LIPLEG trial, published in The Lancet, finally gave women something better: across 11 sites in Germany, 410 patients with stage I to III lipedema had significantly less pain after liposuction than with conservative therapy. It's the first large-scale, multicenter proof that surgery works.

A kinder way through the system

Even policy got the message. David Anderson's Health Affairs study found that after the 2022 Inflation Reduction Act, insurers responded by lowering premiums and raising deductibles — steadying the ground rather than fleeing markets. And at UCLA, researchers identified how statins — humble cholesterol drugs — may suppress a YAP-driven signaling pathway in liver cells, potentially slowing MASLD-related liver cancer, the most common primary liver cancer.

The thread that ties it together

None of these findings invented a molecule from scratch. They took what exists — a lung drug, a cancer drug, a diabetes drug, a cholesterol drug — and asked, what else can you do? That's the quiet revolution in medicine: the answers aren't always new; sometimes they're just newly seenretas. For everyone living with a chronic disease, this is hope you can hold. The treatment that helps you today might be the one that protects you tomorrow.